Ischemic and bleeding risk after complex percutaneous coronary intervention in patients with or without high bleeding risk

被引:5
|
作者
Yamamoto, Ko [1 ]
Shiomi, Hiroki [1 ]
Morimoto, Takeshi [2 ]
Takeji, Yasuaki [1 ]
Yoshikawa, Yusuke [1 ]
Natsuaki, Masahiro [3 ]
Watanabe, Hirotoshi [1 ]
Tada, Tomohisa [4 ]
Tazaki, Junichi [1 ]
Yamaji, Kyohei [5 ]
Tamura, Toshihiro [6 ]
Ando, Kenji [5 ]
Kadota, Kazushige [7 ]
Furukawa, Yutaka [8 ]
Nakagawa, Yoshihisa [9 ]
Kimura, Takeshi [1 ]
机构
[1] Kyoto Univ, Dept Cardiovasc Med, Grad Sch Med, Kyoto, Japan
[2] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan
[3] Saga Univ, Dept Cardiovasc Med, Saga, Japan
[4] Shizuoka Prefectural Gen Hosp, Div Cardiol, Shizuoka, Japan
[5] Kokura Mem Hosp, Div Cardiol, Kitakyushu, Fukuoka, Japan
[6] Tenri Hosp, Dept Cardiol, Tenri, Nara, Japan
[7] Kurashiki Cent Hosp, Div Cardiol, Kurashiki, Okayama, Japan
[8] Kobe City Med Ctr Gen Hosp, Dept Cardiovasc Med, Kobe, Hyogo, Japan
[9] Shiga Univ Med Sci Hosp, Dept Cardiovasc Med, Kusatsu, Japan
关键词
complex PCI; coronary artery disease; percutaneous coronary intervention; DUAL ANTIPLATELET THERAPY; MONOTHERAPY; TICAGRELOR; EVENTS; STENTS;
D O I
10.1002/ccd.29335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate utility of the complex percutaneous coronary intervention (PCI) criteria in real-world practice. Background Applicability of procedural complexity criteria for risk stratification has not been adequately evaluated in real-world practice. Methods Among 13,087 patients undergoing first PCI in the CREDO-Kyoto registry cohort-2, the study population consisted of 7,871 patients after excluding patients with acute myocardial infarction and those without stent implantation. Complex PCI was defined as PCI, which fulfills at least one of the followings: three vessels treated, > = 3 stents implanted, > = 3 lesions treated, bifurcation with two stents, >60 mm total stent lengths, and target of chronic total occlusion. Results The cumulative incidences of and adjusted risks for the primary ischemic (myocardial infarction/ischemic stroke), and bleeding (GUSTO moderate/severe) endpoints were significantly higher in patients with complex PCI (N= 2,777 [35%]) than in those with noncomplex PCI (N= 5,094 [65%]) (15.4% vs. 10.9%, log-rankp < .001; odds ratio (OR): 1.53, 95% confidence interval (CI): 1.31-1.79,p < .001, and 11.9% vs. 9.9%, log-rankp= .004; OR: 1.24, 95% CI: 1.05-1.46,p= .01). In the 30-day landmark analysis, the higher risks of patients with complex PCI for ischemic and major bleeding events were only seen within 30 days after PCI (ischemic; within 30 days: HR: 2.19, 95% CI: 1.79-2.69,p < .001; beyond 30 days: HR: 1.11, 95% CI: 0.92-1.34,p= .26, and bleeding; within 30 days: HR: 1.56, 95% CI: 1.13-2.16,p= .007; beyond 30 days: HR: 1.11, 95% CI: 0.94-1.31,p= .22). Conclusions Patients with complex PCI as compared with patients with noncomplex PCI had a higher risk for both ischemic and bleeding events mainly within 30 days after PCI.
引用
收藏
页码:E758 / E770
页数:13
相关论文
共 50 条
  • [41] Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding
    Feldman, Alexander
    Suleiman, Khalid
    Bushari, Limor
    Yahalom, Malka
    Rozner, Ehud
    Freedberg, Nahum Adam
    Turgeman, Yoav
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2014, 23 (04) : 227 - 232
  • [42] Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT?
    Valgimigli, Marco
    Landi, Antonio
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2021, 10 (10) : 1125 - 1128
  • [43] Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?
    Angeli, Fabio
    Reboldi, Gianpaolo
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (04) : 221 - 224
  • [44] A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention
    Vetrovec, George W.
    Kaki, Amir
    Dahle, Thom G.
    HEART INTERNATIONAL, 2020, 14 (02): : 92 - 99
  • [45] Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?
    Fabio Angeli
    Gianpaolo Reboldi
    American Journal of Cardiovascular Drugs, 2015, 15 : 221 - 224
  • [46] Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report
    Mahmood, Hamid
    Shahid, Farhan
    Egred, Mohaned
    Farag, Mohamed
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2022, 6 (06)
  • [47] Systemic Inflammation Alters the Bleeding-Ischemic Balance in High-Bleeding Risk Patients Undergoing Percutaneous Coronary Interventions
    Nicolas, Johny
    Cao, Davide
    Claessen, Bimmer E.
    Chiarito, Mauro
    Sartori, Samantha
    Qiu, Hanbo
    Nardin, Matteo
    Camaj, Anton
    Roumeliotis, Anastasios
    Zhang, Zhongjie
    Goel, Ridhima
    Chandiramani, Rishi
    Baber, Usman
    Sweeny, Joseph
    Krishnan, Prakash
    Kini, Annapoorna
    Sharma, Samin K.
    Dangas, George
    Mehran, Roxana
    CIRCULATION, 2020, 142
  • [48] Bivalirudin Vs Unfractionated Heparin during Percutaneous Coronary Intervention in High Risk Patients for Bleeding. AntiCoagulant Regimen In high risk PAtients for Bleeding - ACRIPAB Trial
    Feldman, A.
    Suleiman, K.
    Bushari, L.
    Rozner, E.
    Freedberg, N. A.
    Turgeman, Y.
    EUROPEAN HEART JOURNAL, 2012, 33 : 842 - 842
  • [49] Bleeding Risk and Incidence in Real World Percutaneous Coronary Intervention Patients with Ticagrelor
    Subiakto, Ivan
    ul Haq, Muhammad Asrar
    Van Gaal, William J.
    Heart Lung and Circulation, 2015, 24 (04): : 404 - 406
  • [50] Bleeding Risk in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Comprehensive Review
    Marschall, Alexander
    Rivero, Fernando
    del Val, David
    Bastante, Teresa
    Soberon, Edurne Lopez
    Sanchez, Ines Gomez
    Velasco, Elena Basabe
    Alfonso, Fernando
    Hernandez, Jose Maria de la Torre
    Sanchez, David Marti
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)